Pharmaceutical Interest in Psilocybin Pharmaceutical interest in psilocybin appears to be increasing. As of September 1st, 2018, eighteen clinical trials with psilocybin have been completed. See Global Data Clinical Trials Database. Twenty one …
The psilocybin field is underdeveloped. Only one active ingredient in “magic mushrooms” has been formulated and studied in a meaningful way.
The pharmaceutical industry has failed to create safe and effective chemical compositions for treating mood disorders, such as depression, anxiety, compulsion, addiction, etc.
The psilocybin field needs to shift its focus from “magic mushrooms” to the active molecules within them.
We can make better products for treating mood disorders by formulating naturally occurring psilocybin derivatives.